Triptanophobia in migraine: A case-control study on the causes and consequences of the nonuse of triptans in chronic migraine patients

References

• García-Azorin D, Yamani N, Messina LM, et al. A PRISMA-compliant systematic review of the endpoints employed to evaluate symptomatic treatments for primary headaches. J Headache Pain. 2018 Sep 21;19(1):90.
   PubMedGoogle Scholar
• Charles A. Migraine. N Engl J Med. 2017 Aug 10;377(6):553–561.
   PubMed Web of Science ®Google Scholar
• Marmura W, Silberstein SO, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3–20.
   PubMed Web of Science ®Google Scholar
• Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009 Sep;16(9):968–981.
   PubMed Web of Science ®Google Scholar
• Garrido Cumbrera M, Gálvez Ruiz D, Braçe O. et al. Impacto y situación de la migraña en España: atlas. 1st. Sevilla, Spain: Universidad de Sevilla; 2018.
   Google Scholar
• Fischer M, Frank F, Wille G, et al. Triptans for acute migraine headache: current experience with triptan use and prescription habits in a tertiary care headache outpatient clinic: an observational study. Headache. 2016;56(6):952–960.
   PubMed Web of Science ®Google Scholar
• Adelman JU, Adelman LC, Freeman MC, et al. Cost considerations of acute migraine treatment. Headache. 2004 Mar;44(3):271–285.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002 Oct;22(8):633–658.
   PubMed Web of Science ®Google Scholar
• Goldstein JA, Massey KD, Kirby S, et al. Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia. 2004;24(7):515–521.
   PubMed Web of Science ®Google Scholar
• Electronics medicine compendium. 2018. Sumatriptan 50mg Tablets. Cited 2020 Jan 28. Available from: https://www.medicines.org.uk/emc/product/524/smpc#CONTRAINDICATIONS
   Google Scholar
• Hall GC, Brown MM, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004;62(4):563–568.
   PubMed Web of Science ®Google Scholar
• Feleppa M, Apice G, D’Alessio A, et al. Tolerability of acute migraine medications: influence of methods of assessment and relationship with headache attributes. Cephalalgia. 2008;28(10):1012–1016.
   PubMed Web of Science ®Google Scholar
• Wells RE, Markowitz SY, Baron EP, et al. Identifying the factors underlying discontinuation of triptans. Headache. 2014;54(2):278–289.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Sun-Edelstein C, Druyts E, et al. Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain. 2016;17(1):107.
   PubMedGoogle Scholar
• Dekker F, Wiendels NJ, de Valk V, et al. Triptan overuse in the Dutch general population: a nationwide pharmaco-epidemiology database analysis in 6.7 million people. Cephalalgia. 2011;31(8):943–952.
   PubMedGoogle Scholar
• Weatherall MW. Drug therapy in headache. Clin Med (Lond). 2015 Jun;15(3):273–279.
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Mania M, Lampl C, et al. Poor medical care for people with migraine in Europe – evidence from the eurolight study. J Headache Pain. 2018;19(1):10.
   PubMedGoogle Scholar
• Gracia-Naya M, Alarcia-Alejos R, Modrego-Pardo PJ. Importancia de la migraña crónica en una consulta general de neurología. Rev Neurol. 2008;46:577–581.
   PubMed Web of Science ®Google Scholar
• Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007 Oct 16;4(10):e296.
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (HIS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1–211.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629–808.
   PubMed Web of Science ®Google Scholar
• Buse DC, Reed ML, Fanning KM, et al. Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the american migraine prevalence and prevention (AMPP) study. Headache. 2017 Jan;57(1):31.
   PubMed Web of Science ®Google Scholar
• Sacco S, Merki-Feld GS, Ægidius KL, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017;18(1):108.
   PubMed Web of Science ®Google Scholar
• Ezpeleta D, Pozo-Rosich P Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología. Guía oficial de práctica clínica en cefaleas. 2015. Editorial Luzan 5, Madrid. vol. 53
   Google Scholar
• GBD 2017. Disease and injury incidence and prevalence collaborators. global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018 Nov 10;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Loder EW, Adams AM, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2016 May;56(5):821–834.
   PubMed Web of Science ®Google Scholar
• Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018 Feb;17(2):174–182.
   PubMed Web of Science ®Google Scholar
• Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018 Dec 11;91(24):e2222–e2232.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019 Dec 5;381(23):2230–2241.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Munjal S, Alam A, et al. Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache. 2018 Oct;58(9):1408–1426.
   PubMed Web of Science ®Google Scholar
• Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221–235. DOI:10.1111/head.12601.
   PubMedGoogle Scholar
• Xu H, Han W, Wang J, et al. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016 Dec;17(1):113.
   PubMed Web of Science ®Google Scholar
• Schwedt TJ, Alam A, Reed ML, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2018 May 24;19(1):38.
   PubMed Web of Science ®Google Scholar
• Woolley JM, Bonafede MM, Maiese BA, et al. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017 Oct;57(9):1399–1408.
   PubMed Web of Science ®Google Scholar
• Ahna AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain. 2005 May;115(1–2):1–4.
   PubMed Web of Science ®Google Scholar
• Moreno-Ajona D, Chan C, Villar-Martínez MD, et al. Targeting CGRP and 5-HT1F receptors for the acute therapy of migraine: a literature review. Headache. 2019 Jul;59(Suppl 2):3–19.
   PubMedGoogle Scholar
• Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM, et al. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018;186:88–97.
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001 Jul 11;286(2):180–187.
   PubMed Web of Science ®Google Scholar
• Mahmoud AN, Mentias A, Elgendy AY, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open. 2018 Mar 27;8(3):e020498.
   PubMed Web of Science ®Google Scholar
• Mathew S, Ailani J. Traditional and novel migraine therapy in the aging population. Curr Pain Headache Rep. 2019;23(6):42.
   PubMed Web of Science ®Google Scholar
• Meyler WJ. Side effects of ergotamine. Cephalalgia. 1996 Feb;16(1):5–10.
   PubMed Web of Science ®Google Scholar
• Tajti J, Majláth Z, Szok D, et al. Drug safety in acute migraine treatment. Expert Opin Drug Saf. 2015 Jun;14(6):891–909.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb;43(2):144–166.
   PubMed Web of Science ®Google Scholar
• Straube A, Pfaffenrath V, Ladwig KH, et al. Prevalence of chronic migraine and medication overuse headache in Germany–the German DMKG headache study. Cephalalgia. 2010;30(2):207–213.
   PubMed Web of Science ®Google Scholar
• Meskunas CA, Tepper SJ, Rapoport AM, et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006;46(5):766–772.
   PubMed Web of Science ®Google Scholar
• Ministerio de Trabajo, Migraciones y Seguridad Social. Guía Laboral - Prestaciones del Régimen General de la Seguridad Social. Cited 2020 Jan 29. Available from: http://www.mitramiss.gob.es/es/Guia/texto/guia_14/contenidos/guia_14_29_2.htm
   Google Scholar
• Lipton RB. Risk factors for and management of medication-overuse headache. Continuum (Minneap Minn). 2015 Aug;21(4Headache):1118–1131.
   PubMedGoogle Scholar
• Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015 Mar;55(Suppl 2):103–122. quiz 123-6.
   PubMedGoogle Scholar